About US
Contact us
-
GlaxoSmithKline gets no payday from high-profile trade-secrets theft caseAfter years of battling in courtand securing guilty pleas from two former GlaxoSmithKline researchers, federal prosecutors have come up short inconvincing the court to orderrestitution in a closely w2021/6/18
-
Building its world-leading flu vaccine capacity, Sanofi scores FDA nod for $425M plant in PAThree months after revealing a plan to build a €600 million flu vaccine plant in Toronto, Sanofi received good news about another flu shot factoryin North America. The FDA hasapprovedSanofi'snewly co2021/6/18
-
Danaher strikes $9.6B buyout for next-gen contract manufacturing player AldevronLooking to make a big splash in the next-gen pharma manufacturing market, Danaher haslaid out$9.6 billion to buy leading contract manufacturer Aldevron. Aldevron, founded in 1998, is a global player2021/6/16
-
BIO 2021: After COVID-19 showcased the power of science, J&J exec urges industry to start thinking 'cure' in cancerAmid COVID-19 lockdowns, routine cancer screenings were put on the back burner. While that may be a short-term harm from the pandemic, the crisis also showed the world that science can solve tough pr2021/6/16
-
While mRNA saved the COVID-19 day, GSK and Sanofi vaccines likely safe beyond pandemic: analystsFew knew about mRNA technology before the pandemic ushered the novel approach to the forefront of the fight against COVID-19. But while mRNA shots sailed through testing and have reached hundreds of2021/6/14
-
Long-suffering Dendreon finds new avatar as contract manufacturer for cell therapy partnersFiling for bankruptcy in 2014 might have seemed the end for Dendreon.But seven years later—and three rounds of being bought and sold—the company has resurfaced. This week,Dendreonrevealedplans to est2021/6/14
-
Novartis extends operations at U.K. plant for another year, keeping some 200 workers on boardAs Novartis shifts away from the production of older, less profitable drugs, the drugmaker has placeda slew of production facilitiesin the cost-cutting crosshairs. But with the company facingincrease2021/6/11
-
Vexed by vectors: How COVID-19 vaccine and cell and gene players are tackling the viral vector bottleneckBristol Myers Squibb’s cancer cell therapy Breyanzi. Johnson & Johnson and AstraZeneca’s recombinant COVID-19 vaccines. Novartis’ gene therapy Zolgensma. All of these, plus many others, are unite2021/6/11
-
Change to Gilead assistance program threatens PrEP access, HIV advocates sayDr. John Carlo is concerned that patients at Prism Health North Texas who rely on the health care safety net will soon be struggling even more to stay on PrEP, a medication that prevents HIV transmis2021/6/9
-
Biogen's hefty Aduhelm cost sparks even more talk of a drug pricing crackdown. But will it happen?A $56,000 annual price tag for a drug with questionable credentials? Let the feeding frenzy begin for politicians who have long supported drug price reform and now have a poster child for their cause2021/6/9